www.aids2014.org
How can you control DR virus?
ARV Therapy
CTL Response
Mut
ation Reversion
Pharmacological Control
Immune Control
Prevent viral DR mutation Enhance immune responses
www.aids2014.org
Peptide design and Elispot assay
49 patients
218 peptides
140 pairs (WT Vs. DR)
Protease and Reverse Transcriptase
Epitopes overlapping DR mutations sites were selected.
www.aids2014.org
High-magnitude ELISpot responses both to WT and DR variants
DR - WT
Higher recognition of DR
Higher recognition of WT
www.aids2014.org
Most recognized peptides. (>20%)
NLLTQIGCT
GRNLLTQIG
RNLMTQIGC
QHLLRWGLY
EELRQHLLRW
KMIGGVGGFI
ITLWQRPIV
DTVIEEMNL
WT
DR
WT
DR
WT
DR
DR
DR
Peptides with DR mutations were frequently recognized.
www.aids2014.org
SummaryPeptides including DR mutations could be considered as immunogens in therapeutic CTL vaccines directed towards immunological-pharmacological strategies to control HIV.
Therapeutic CTL vaccines could prevent selection of DR variants in places where continuous medication supply has not been achieved.
Therapeutic CTL vaccines could control viremia in patients with failure to multiple ART schemes.
www.aids2014.org
Abstract number: WEPDA0102
IrsiCaixaInstitut de Recerca de la Sida
Top Related